IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
UP-0221134
(2008-07-30)
|
등록번호 |
US-7598353
(2009-10-20)
|
발명자
/ 주소 |
- Bowdish, Katherine S.
- McWhirter, John
- Kretz Rommel, Anke
- Maruyama, Toshiaki
|
출원인 / 주소 |
- Alexion Pharmaceuticals, Inc.
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
5 인용 특허 :
21 |
초록
▼
Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or b
Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
대표청구항
▼
We claim: 1. A fusion molecule comprising: a first portion that targets cells bearing the OX-2/CD200 antigen, wherein the first portion is an anti-CD200 antibody or antigen binding fragment thereof that binds to CD200 comprising: (i) a light chain CDR1 having the sequence set forth in residues 26-3
We claim: 1. A fusion molecule comprising: a first portion that targets cells bearing the OX-2/CD200 antigen, wherein the first portion is an anti-CD200 antibody or antigen binding fragment thereof that binds to CD200 comprising: (i) a light chain CDR1 having the sequence set forth in residues 26-36 of SEQ ID NO: 209, (ii) a light chain CDR2 having the sequence set forth in residues 52-58 of SEQ ID NO: 209, (iii) a light chain CDR3 having the sequence set forth in residues 91-99 of SEQ ID NO: 209, (iv) a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 149, (v) a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 174, and (vi) a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 195; and a second portion that is a toxin. 2. The fusion molecule of claim 1, wherein said toxin is selected from the group consisting of a plant toxin and a fungal toxin. 3. The fusion molecule of claim 2, wherein said plant toxin is selected from the group consisting of ricin A chain, abrin A chain, modeccin A chain, Aleurites fordii proteins, Dianthin proteins, Phytolacca americana proteins, Morodica charantia inhibitor, curcin, crotin, Saponaria officinalis inhibitor, and gelonin. 4. The fusion molecule of claim 2, wherein said fungal toxin is selected from the group consisting of restrictocin, alpha sardine, and mitogillin. 5. The fusion molecule of claim 1, wherein said toxin is selected from the group consisting of adriamycin, chlorambucil, daunomycin, methotroxate, neocarzinostatin, and platinum. 6. The fusion molecule of claim 1, wherein said toxin is selected from the group consisting of granzyme B, perform, TNF-α, and IFN-α. 7. The fusion molecule of claim 1, wherein said first portion is an antigen binding fragment of an anti-CD200 monoclonal antibody. 8. The fusion molecule of claim 1, wherein the anti-CD200 antibody is a humanized antibody, or an antigen binding fragment thereof. 9. The fusion molecule of claim 1, wherein the antigen binding fragment is selected from the group consisting of an Fv, scFv, Fab' and F(ab')2. 10. A composition comprising a fusion molecule of claim 1 and a pharmaceutically acceptable carrier. 11. The fusion molecule of claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region having the sequence set forth in SEQ ID NO: 203. 12. The fusion molecule of claim 1, wherein the antibody or antigen-binding fragment comprises a light chain variable region having the sequence set forth in SEQ ID NO: 209. 13. The fusion molecule of claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region having the sequence set forth in SEQ ID NO: 203 and a light chain variable region having the sequence set forth in SEQ ID NO: 209.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.